Yoshinori Matsumoto

Medicine & Life Sciences

1. Systemic Lupus Erythematosus 100%
2. Osteoblasts 93%
3. Vasculitis 91%
4. Glucocorticoids 86%
5. Antineutrophil Cytoplasmic Antibodies 79%
6. Bone Morphogenetic Proteins 65%
7. Bone Morphogenetic Protein 2 48%
8. Fibroblast Growth Factor 8 41%
9. Granulomatosis with Polyangiitis 41%
10. Cross-Sectional Studies 41%
11. Aldosterone 39%
12. Bone and Bones 33%
13. Takayasu Arteritis 33%
14. Transcription Factors 32%
15. Phosphorylation 32%
16. Registries 31%
17. Osteoclasts 31%
18. Protein-Tyrosine Kinases 30%
19. Prednisolone 30%
20. Antibodies 29%
21. Cherubism 29%
22. Remission Induction 28%
23. Ligases 27%
24. Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis 27%
25. Bone Morphogenetic Protein Receptors 27%
26. Estrogens 27%
27. Tumor Necrosis Factor-alpha 27%
28. Cyclophosphamide 26%
29. Cohort Studies 25%
30. Growth Differentiation Factor 10 25%
31. Ubiquitin 25%
32. Recurrence 25%
33. Ulcerative Colitis 24%
34. Rheumatoid Arthritis 24%
35. Serratia marcescens nuclease 24%
36. Breast Neoplasms 24%
37. Prospective Studies 24%
38. Bone Morphogenetic Protein 6 22%
39. Cluster Analysis 22%
40. Bone Morphogenetic Protein 4 22%
41. Cathepsin E 22%
42. Kidney 21%
43. Lupus Nephritis 21%
44. Tankyrases 21%
45. Estradiol 21%
46. Rituximab 21%
47. Cell Proliferation 20%
48. pristane 20%
49. Linagliptin 20%
50. Peroxisome Proliferator-Activated Receptors 20%